Retatrutide · research summary

Anti-Obesity Medications in Longevity and Aesthetic Medicine.

Journal of clinical medicine · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Narrative review
“This narrative review (PubMed, EMBASE, Scopus, Web of Science, Cochrane Library, and Clinical trial registries; January 2010–June 2026) integrates mechanistic studies, randomised cardiovascular and renal outcome trials, ageing-biomarker analyses, body-composition data, and patient-facing aesthetic phenomena.”

Duration

Literature search period from January 2010 to June 2026
“PubMed, EMBASE, Scopus, Web of Science, the Cochrane Library, and ClinicalTrials.gov were searched for records published between January 2010 and June 2026.”

Reported findings

Anti-obesity medications reduce major cardiovascular events, slow kidney and liver disease progression, and lower all-cause mortality in selected populations.
“The evidence indicates that AOMs reduce major cardiovascular events, slow kidney and liver disease progression, and lower all-cause mortality in selected populations; exploratory proteomic and epigenetic analyses further suggest effects partly independent of weight loss, though these do not establish slowed ageing.”
Newer multi-receptor agents preferentially reduce visceral and hepatic fat, with liver-fat reductions of roughly 60–80%.
“Newer multi-receptor agents act with greater metabolic specificity: glucagon-containing agents such as survodutide and the triple agonist retatrutide preferentially reduce visceral and hepatic fat (liver-fat reductions of roughly 60–80% in places), a quality of weight loss arguably more relevant to healthspan than its quantity.”
Rapid large-magnitude weight loss drives soft-tissue and appearance changes colloquially termed “Ozempic face” and “Ozempic body”, alongside accelerated skin laxity and loss of lean mass.
“Concurrently, rapid large-magnitude weight loss drives soft-tissue and appearance changes colloquially termed “Ozempic face” and “Ozempic body”, alongside accelerated skin laxity and loss of lean mass, the latter tempered by data showing lean-loss proportions comparable to established agents.”

Source: PubMed 42590128 · DOI 10.3390/jcm15156026 · all study summaries

Study type

Narrative review

“This narrative review (PubMed, EMBASE, Scopus, Web of Science, Cochrane Library, and Clinical trial registries; January 2010–June 2026) integrates mechanistic studies, randomised cardiovascular and renal outcome trials, ageing-biomarker analyses, body-composition data, and patient-facing aesthetic phenomena.”

Reported findings

Anti-obesity medications reduce major cardiovascular events, slow kidney and liver disease progression, and lower all-cause mortality in selected populations.

“The evidence indicates that AOMs reduce major cardiovascular events, slow kidney and liver disease progression, and lower all-cause mortality in selected populations; exploratory proteomic and epigenetic analyses further suggest effects partly independent of weight loss, though these do not establish slowed ageing.”

Newer multi-receptor agents preferentially reduce visceral and hepatic fat, with liver-fat reductions of roughly 60–80%.

“Newer multi-receptor agents act with greater metabolic specificity: glucagon-containing agents such as survodutide and the triple agonist retatrutide preferentially reduce visceral and hepatic fat (liver-fat reductions of roughly 60–80% in places), a quality of weight loss arguably more relevant to healthspan than its quantity.”

Rapid large-magnitude weight loss drives soft-tissue and appearance changes colloquially termed “Ozempic face” and “Ozempic body”, alongside accelerated skin laxity and loss of lean mass.

“Concurrently, rapid large-magnitude weight loss drives soft-tissue and appearance changes colloquially termed “Ozempic face” and “Ozempic body”, alongside accelerated skin laxity and loss of lean mass, the latter tempered by data showing lean-loss proportions comparable to established agents.”